Skip to main content

Table 2 Cox regression models on overall survival and progression-free survival

From: Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

  Overall survival Progression-free survival
Factors Univariate HR, 95% CI, P-value Multivariate HR, 95% CI, P-value Univariate HR, 95% CI, P-value Multivariate HR, 95% CI, P-value
Sex (M vs F) 1.71 (0.96–3.05), P = 0.07   1.35 (0.82–2.21) P = 0.24  
Age (years) 1.00 (0.98–1.02), P = 0.72   1.00 (0.98–1.01) P = 0.74  
Lines of treatment: P = 0.55   P = 0.63  
 2 vs 1 1.23 (0.57–2.64)   1.06 (0.56–1.99)  
  ≥ 3 vs 1 1.56 (0.69–3.55)   1.35 (0.67–2.73)  
BRAF (mutant vs wild-type) 1.14 (0.64–2.04), P = 0.65   1.32 (0.80–2.19) P = 0.28  
Brain metastases (yes vs no) 1.03 (0.56–1.87), P = 0.93   1.30 (0.77–2.18) P = 0.32  
Lactate dehydrogenase (≥454 vs < 454) 3.06 (1.69–5.57), P < 0.0001 2.51 (1.36–4.64), P = 0.003 2.16 (1.18–3.99) P = 0.01 1.74 (1.03–2.94) P = 0.04
Absolute neutrophil count (≥5.4 vs < 5.4) 2.04 (1.17–3.57), P = 0.01   1.60 (0.98–2.61) P = 0.06  
White blood cell count (≥7.6 vs < 7.6) 1.57 (0.91–2.73), P = 0.11   1.55 (0.95–2.54) P = 0.08  
Neutrophil-to-lymphocyte ratio (≥5.0 vs < 5.0) 3.53 (2.02–6.16), P < 0.0001 2.85 (1.60–5.08), P < 0.0001 2.53 (1.53–4.18) P < 0.0001 2.10 (1.23–3.59) P = 0.007
Derived neutrophil-to-lymphocyte ratio (≥3.0 vs < 3.0) 2.70 (1.55–4.69), P < 0.0001   2.50 (1.48–4.23) P = 0.001